These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24359526)

  • 21. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Liu Y; Kwiatkowski DJ
    Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
    Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
    Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
    Xu G; Wu K; Wang XP; Zhao S
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):986-91. PubMed ID: 16060994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
    Li J; Wang R; Schweickert PG; Karki A; Yang Y; Kong Y; Ahmad N; Konieczny SF; Liu X
    Cell Cycle; 2016; 15(5):711-9. PubMed ID: 26890815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
    Koh SB; Wallez Y; Dunlop CR; Bernaldo de Quirós Fernández S; Bapiro TE; Richards FM; Jodrell DI
    Cancer Res; 2018 Jun; 78(11):3054-3066. PubMed ID: 29735549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
    Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
    Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
    Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
    Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
    Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
    Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
    Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
    Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.